Safety, Tolerability and Pharmacokinetics After Continuous Infusion of KAND567

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2020
The study was planned to consist of 24 healthy subjects in 3 dosing cohorts receiving a continuous i.v. infusion of KAND567 or placebo for 6 h (6 subjects on active and 2 subjects on placebo per cohort), with the option of two additional cohorts of the same size and group composition.
Epistemonikos ID: 429bd029fadfaa11d73d7e92b4bab016ae1f2f7f
First added on: May 15, 2024